B. Riley raised the firm's price target on Theravance Biopharma (TBPH) to $17 from $14 and keeps a Neutral rating on the shares. The final generic settlement with Mankind (MNKD) locks exclusivity through April 2039, "removing the last overhang on a clean single-asset story," the analyst tells investors.
